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Abstract
Background: The population-based incidence of sarcoma and its histological subtypes in Germany is unknown.
Up-to-date information on a disease with an incidence comparable to other cancer entities is of high public health
relevance. The aim of this study was to determine this incidence and to detect significant changes in incidence
trends using data from German epidemiological cancer registries.
Methods: Pooled data from the German Centre for Cancer Registry Data with a primary diagnosis occurring in
2013 were used. To date, this is the latest data on cancer incidence available for Germany. All German cancer
registries with sufficient completeness were included (10 out of 11), covering a population of 70.0 million people,
representing 87% of the German population. All malignant sarcomas according to the RARECARE Project and the
WHO classification 2002 were considered for analysis and, above all, gastrointestinal stromal tumours (GIST) of
uncertain behaviour. Sensitivity analysis was performed excluding certain histologies.
Results: The analysis included 3404 cases in men and 3442 cases in women diagnosed in 2013. The age adjusted
sarcoma incidence (European standard) was 7.4 (men) and 6.6 (women) per 100,000 inhabitants. About 70% of
sarcomas were soft tissue sarcomas, about 22% GIST, and about 9% bone sarcomas. The most common histological
subtypes besides GIST were fibrosarcomas (14%) and liposarcomas (12%) in men and complex mixed and stromal
neoplasms (22%), non-uterine leiomysarcomas (10%) and fibrosarcomas (9%) in women. Considering the trend for
the years of diagnosis 2004 to 2013, there was a significant increase in incidence for GIST while the incidence of
soft tissue sarcomas (only men) as well as of bone sarcoma stayed constant over time. As to soft tissue sarcoma in
women, the incidence stayed constant up to the year 2009 and significantly decreased afterwards.
Conclusion: This study is the first detailed analysis of a German-wide population-based sarcoma incidence showing
results comparable to the incidence detected in the RARECARE Project.
Keywords: Sarcoma, Incidence, Histology, Germany, Gastrointestinal Stromal tumours, Topography, Medical,
Neoplasms
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Background
Sarcomas form a heterogeneous group of neoplasia
emerging from mesenchymal cells [1] and can occur at
almost any site of the body. According to their origin,
their morphology, and their molecular genetic changes,
they are divided into many different histological categor-
ies, which are mainly classified into two main groups:
soft tissue and bone sarcomas [1–3].
Sarcomas account for less than 1% of all malignant
tumours worldwide and thus are rare [1, 4]. However, up-
to-date information on a disease with an incidence com-
parable to other cancer entities like cancer of the central
nervous system is of high public health relevance [4].
Most analyses of cancer incidence are site-based, e.g.
according to the International Classification of Diseases
(ICD) [ICD-10]. In site-based classifications, there is no
separate coding for sarcomas. Sarcomas emerge from
many different sites [5]. Hence, sparse information is
available on the incidence of all sarcoma subtypes.
An age-standardized incidence rate (2000 US stand-
ard) of 5.0 per 100,000 for soft tissue sarcomas was
found in the SEER (Surveillance, Epidemiology and End
results) program in the USA (years of diagnosis 1978–
2001) [5].
The project “Surveillance of rare cancer in Europe”
(RARECARE) provided an estimated incidence for 64
European cancer registries for cases diagnosed between
1995 and 2002 [6] of 4.2 for soft tissue sarcomas, 0.8 for
bone sarcomas, and 0.1 for GIST (age-standardized
(European standard), per 100,000). Further individual
European studies with similar results exist [7, 8], but, to
our knowledge, there is only one hospital-based study
on sarcoma incidence in Germany [9].
The aim of this study was to determine the incidence
of all sarcomas and their subtypes for Germany and to
detect statistical significant changes in incidence in the
last 10 years. For this purpose, data from the German
epidemiological cancer registries provided by the
German Centre for Cancer Registry Data (ZfKD) (data
call December 2015; data supply from ZfKD January
2017) were used. To date, this is the latest data on can-
cer incidence available for Germany.
Methods
Data
In Germany, 11 population-based cancer registries
covering the entire country exist. At the time of the data
call, diagnoses up to the year 2013 were considered as
sufficiently complete to be eligible for analysis. The
cancer registry of Baden-Wuerttemberg had to be ex-
cluded as it was still being established in 2013. For trend
analyses considering the years of diagnosis from 2004 to
2013, Hessen and Nordrhein-Westfalen (except for the
district of Muenster) had to be excluded as well as they
were considered complete only after the year 2004 by
the ZfKD.
All malignant sarcomas according to the RARECARE
Project [6, 10] and the WHO classification [1, 3, 11]
were considered for analysis (Table 1) and, above all,
GIST of uncertain biological behaviour. They were clas-
sified into 16 histological groups (Table 1) according to
the classifications of the ICD-O-3 [12] and the WHO
2002 [1]. The complex neoplasia group consists of
tumours of uncertain differentiation according to the
WHO classification 2002 [1] (complex mixed and stro-
mal neoplasia (ICD-O-3 Morphology (ICD-O-3 M)
8930–8991), synovial-like neoplasms (9040–9044)) and
the malignant glomus tumour (8711). Above this,
sarcomas were grouped into three entities: soft tissue
sarcomas (all sites except bone (ICD-O-3 Topography
(ICD-O-3 T) C40.0-C41.9); all included histologies ex-
cept GIST (ICD-O-3 M 8936)), bone sarcomas (ICD-O-
3 T C40.0-C41.9; all included histologies except GIST
(ICD-O-3 M 8936)) and GIST (ICD-O-3 M 8936/3,
8936/1). This is modified from the RARECARE project
classification of sarcomas into four main groups (tiers)
[6, 10]. In contrast, we grouped the malignant GIST
(8936/3) together with the GIST of uncertain malignant
potential (ICD-O-3 8936/1), as the behaviour. is often
hard to define in these entities. Kaposi sarcomas were
not grouped as a separate entity due to the small num-
ber of cases. However, they were considered as a
Table 1 Classification of histological groupsa
Histological group ICD-O-3 Morphology
Sarcomas NOS 8800–8806
Fibrosarcomas 8810–8840
Liposarcomas 8850–8881
Uterine leiomysarcomas 8890–8896, ICD-O-3
Topography C53, C54
Non-uterine leiomyosarcomas 8890–8896, ICD-O-3
Topography not C53, C54
Rhabdomyosarcomas 8900–8921
Complex mixed and stromal
neoplasms (ICD-O-3), Others
8711, 8930–8991, 9040–9044,
9580–9581
Phylloides tumour 9020
Angiosarcomas 9120–9175
Osteosarcomas 9180–9210
Chondosarcomas 9220–9243
Giant cell neoplasia 9250–9252
Ewing family of tumours 9260, 9364, 9365
Malignant ameloblastomas 9261, 9310
Chordomas 9370–9373
Nerve sheath tumours 9540–9571
aaccording to the third edition of the International Classification of Diseases
for Oncology, Morphology (ICD-O)
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separate group according to histology for the sub-
analysis. Sensitivity analyses were performed excluding
certain histologies according to the opinion of experts or
because they are missing in the WHO classification from
2002 (see Additional file 1: Table S1).
To compare the distribution of histological groups be-
tween different regions of the body, soft tissue sarcomas
were classified into six different sites: head and neck,
limbs, trunk, thorax, abdomen, and pelvis (see
Additional file 2: Table S2). We chose to classify tumours
in accordance with other studies in order to achieve
optimal comparability. Consequently, some codes may
have been summarized into the same categories although
treatment strategies show relevant differences (e.g. classifi-
cation of C48 into trunk tumours).
Information on the general population numbers was
taken from the German Federal Statistical Office [13]. In
total, a population of 69.95 million people representing
87% of the German population (key date December 31st,
2012) were included.
Analysis
To determine the incidence of all sarcomas and their
subtypes for Germany, incidence rates were calculated
as the number of cases per 100,000 inhabitants, age-
standardized by the European standard population 1976.
Rates were analysed by sex and by year (2004 to 2013).
In addition, age-specific rates in 5-year age bands were
estimated, and subgroup analyses according to the sar-
coma entity, histological groups, most frequent histolo-
gies, and federal states were performed. For all analyses
stratified by federal state, cumulated frequencies and
rates for the years 2009 to 2013 including 95% confi-
dence intervals (95% CI) were calculated, dividing the
cumulated numbers of cases by the corresponding
cumulated population under risk.
For trend analyses, the most recent ten-year-period
(2004 to 2013) was considered in order to enable valid
analyses. In order to detect statistically significant changes
in incidence in the last 10 years, annual percentage
changes (APC) in the trend of the incidence rates were
calculated with the statistical software Joinpoint (Joinpoint
Regression Program, Version 4.4.0.0. January 2017; Statis-
tical Research and Applications Branch, National Cancer
Institute). Joinpoint uses log-linear regression to fit
models with a minimal number of joinpoints (where rates
change significantly) and estimates APCs and 95% confi-
dence intervals for each section (between joinpoints):
With no joinpoint, one APC was derived, with up to one
joinpoint, an AAPC (average APC) was calculated. The
slope of the regression line was tested to see if it was sig-
nificantly different from zero.
Other analyses were performed with the software SAS
9.4 (SAS Institute, Cary NC).
Cases with unknown or unspecific histologies had to
be excluded as it is unknown whether they were sarco-
mas. Hence, the number of sarcomas excluded is not
possible to determine.
Results
Descriptive epidemiology and incidence rates according
to sarcoma entities
In the year 2013, 6846 sarcoma cases were diagnosed in
Germany (excluding Baden-Wuerttemberg) and reported to
a German cancer registry (3404 men, 3442 women, Table 2).
Soft tissue sarcomas were the most frequent entity (70%
in men and 74% in women), followed by GIST (22% in
men and 18% in women) and bone sarcomas (9% in men
and 8% in women). There was about the same number of
male cases as female ones (ratio men/women 1:1).
However, the age-standardized incidence rate per 100,000
was higher in men than in women (7.4 (95% confidence
interval (CI): 7.2–7.7) versus 6.6 (95% CI: 6.3–6.8). For
soft tissue sarcomas, there were slightly more female than
male cases (ratio men/women 1:1.1). For bone sarcomas
and GIST, it was vice versa (ratio men/women 1.1:1 and
1.2:1 respectively).The age-standardized incidence rates
were higher for men than for women for all entities.
Excluding certain histologies according to expert opin-
ion or because they were not mentioned in the WHO
classification 2002 did not considerably alter these re-
sults in men (Table 2). In women, the exclusion of
Mullerian mixed tumours (ICD-O-3 M 8950/3) resulted
in a slightly lower incidence in women.
The median age at diagnosis for all sarcomas was similar
in men and women (67.4 and 67.7 respectively, Table 2).
While GIST cases were about 2 years older at the time of
diagnosis than all other sarcoma patients, bone sarcoma
patients were much younger (49.8 (men) and 54.0 years
(women) respectively).
For all sarcomas combined, there were more male
cases than female ones in the two youngest age groups
(Table 2). Above the age of 30, the ratio was reversed or
balanced. The incidence steadily increased with age.
Regarding 5-year age groups stratified by sarcoma entity
(Fig. 1), it appeared that for all entities, the incidence
decreased again at ages above 85 (except for soft tissue
and bone sarcomas sarcomas in men). As well, the age
distribution differed for bone sarcomas, showing a first
peak at ages 10 to 19 and a second peak at ages above
85 for men and of 75 to 79 for women (Fig. 1).
Subanalysis according to histological groups
The five most important histological groups were fibrosar-
coma, liposarcoma, complex neoplasia, non-uterine leio-
myosarcoma, and GIST, altogether representing more
than half of all sarcomas (60% in men and 65% in women)
(Table 3). Sarcomas which were not otherwise specified
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accounted for a considerable percentage of cases in both
sexes (19% in men and 14% in women). The group of
complex neoplasia was much more common in women
than in men (sex ratio men/women 1:4.4) as carcinosar-
comas including the Mullerian mixed tumour and endo-
metrial stromal sarcomas are exclusively gynaecological
tumours. The median age at diagnosis and the sex ratio
differed considerably between the histological groups.
The distribution of histological groups depended on
the site (see Additional file 3: Figure S1). While fibrosar-
comas and angiosarcomas were the most predominant
types in the head and neck, fibrosarcomas, liposarcomas
and non-uterine leiomyosarcoma were most prominent
in the limbs and trunk. In the thorax, 39% (men) and
36% (women) of sarcomas were not otherwise specified,
and 22% (men) or 15% (women) had complex neoplasia.
Angiosarcoma and fibrosarcoma were also common. In
the abdomen, GIST represented 80% of sarcomas in
both sexes. In the pelvis, distribution of histological
groups differed considerably by sex. While in men,
liposarcomas, non-uterine leiomyosarcomas, and rhabdo-
myosarcomas represent 64% of sarcoma cases, in women,
complex neoplasia accounted for 71% of histologies. For
bone sarcomas, about 34% were chondrosarcomas, about
26% osteosarcomas, and about 16% belonged to the Ewing
family of tumours (data not shown).
Regarding the trend analysis for the years 2004 to
2013 (Fig. 2), there was a significant increase in inci-
dence for men from 6.2 to 7.3 (APC 1.8% (95%-CI: 1.0
to 2.6)) and from 6.4 to 6.7 (AAPC 0.4% (95%-CI: 0.1 to
0.8)) for women (Table 4). It was due to a significant in-
crease in incidence of GIST for both sexes: from 0.8 to
1.6 (APC 8.1% (95%-CI: 6.0 to 10.2)) in men and from
0.6 to 1.1 (APC 7.6% (95%-CI: 5.7 to 9.5)) in women.
The incidence of soft tissue sarcomas (men) (APC 0.9%
(95%-CI: -0.2 to 1.9)) as well as of bone sarcoma (both
sexes, APC -1.1% (95%-CI: -3.1 to 0.9) for men and APC
-0.5% (95%-CI: -2.0 to 1.1) for women) stayed constant
over time (all incidence rates per 100.000, age-
standardized according to European standard). As to soft
a
b
Fig. 1 Age-specific incidence of sarcomas (per 100,000, according to the European standard 1976), year of diagnosis 2013. a Men; b Women
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tissue sarcoma in women, the incidence stayed con-
stant up to the year 2009 and significantly decreased
afterwards (one joinpoint detected). This lead to a de-
crease in the overall incidence of sarcoma after 2009
in women.
The sarcoma incidence differed significantly between
federal states in Germany (Table 5). For all sarcomas, it
ranged between 5.5 (95%-CI: 5.0–6.1) (Sachsen-Anhalt)
and 7.8 (95%-CI: 7.5–8.0 (Nordrhein-Westfalen) or 7.0–
8.6 (Hamburg)) in men and between 5.2 (95%-CI: 4.7–
Table 4 Annual percentage change for incidence rates of sarcomas (all federal states except Baden-Wuerttemberg and Hessen; only
Muenster for Nordrhein-Westfalen)
Men Women
Cases Incidence Ratea Change of Incidence Rate Cases Incidence Ratea Change of Incidence Rate
2004 2013 2004 2013 APCb (%) [95% CI] 2004 2013 2004 2013 APCb(%) [95% CI]
All sarcoma 1752 2373 6.17 7.32 1.8 (1.0;2.6)* 2191 2463 6.44 6.66 0.4 (0.1;0.8)*,**
Soft tissue sarcoma 1256 1614 4.38 4.94 0.9 (−0.2;1.9) 1763 1816 5.11 4.85 −0.7 (−1.3;-0.1)*,**
Bone sarcoma 239 209 0.95 0.82 −1.1 (−3.1;0.9) 194 189 0.70 0.70 −0.5 (−2.0;1.1)
GIST 257 550 0.84 1.55 8.1 (6.0;10.2)* 234 458 0.63 1.12 7.6 (5.7;9.5)*
aage-standardized incidence rates per 100,000 (European standard 1976)
bAPC = Annual Percentage Change
*statistically significant change (p < 0.05)
**one joinpoint detected, result for AAPC (Average annual percentage change)
a
b
Fig. 2 Trends of incidence rates for sarcoma entities, 2004–2013*. a Men; bWomen. *per 100,000; age-standardized according to the European
standard 1976, Hessen excluded, Nordrhein-Westfalen only Muenster region
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5.8) (Sachsen-Anhalt) and 8.7 (95%-CI: 7.9–9.5) (Hamburg)
in women (all incidence rates per 100,000, age-
standardized). Within the sexes, the confidence inter-
val of the federal state with the lowest incidence did not
overlap with the one of the federal state with the highest
incidence. Analyses for sarcoma subtypes were not sens-
ible due to low case numbers in small federal states.
Discussion
This study based on ten German population-based can-
cer registries and 6846 sarcoma cases diagnosed in 2013
examined the overall incidence of sarcomas in Germany
and investigated whether there were statistically signifi-
cant changes in incidence in the last 10 years. Analyses
were based on the latest data available at present.
In general, the age-standardized incidence rates corres-
pond well with the results from other studies [6–8, 10].
Trautmann et al. found higher age-adjusted (European
standard) rates for bone sarcomas (2.6 per 100,000 for
men and 1.8 for women) [9].
Regarding GIST, the age-standardized incidence rates
(European standard) found in the literature were lower
than in the presented study (0.1 to 0.9 per 100,000; men
and women combined) [6, 8]. However, it was not expli-
citly stated whether GIST of unknown behaviour (ICD-
O-3 8936/1), which represent a considerable proportion
of all GIST, were included in analyses, as was done in
our study. The significant increase in incidence for all
sarcomas in the present study was due to a significant
increase in incidence of GIST for both sexes as found in
literature [14–16]. It can partly be explained by the in-
creasing reliability of diagnosis due to the routine use of
markers like CD 117 and DOG1 and because of the in-
creasing awareness of the diagnosis by physicians [15, 16].
Before the third revision of the ICD-O classification
(International Classification of Diseases for Oncology)
[12] which has been introduced in 2003 in Germany, a
separate code for GIST did not exist.
Excluding certain histologies according to expert opin-
ion or because not being mentioned in the WHO classi-
fication 2002 did not considerably alter the results in
men as they only accounted for a small number of cases.
In women, after excluding Mullerian mixed tumours,
the age-standardized incidence was lower than in men
for soft tissue sarcomas. This is in accordance with other
studies where they have been excluded as well [7–9].
The median age at diagnosis found in the present
study was five to 10 years higher than in the literature
for all entities [8, 16]. This may be partly due to the
present study reporting more recent data with an ageing
society in general. As well, in hospital-based studies [8],
elderly patients who have not been treated in a hospital
may have been missed.
The increasing incidence with age up to the ages of 80
to 84 and the decrease in the eldest age-group are in ac-
cordance with findings in the literature [8, 9, 14] and
with most other cancer entities. It is usually explained
by the lack of intensive diagnostic and treatment in
Table 5 Cases and age-standardized incidencea, by federal state, years of diagnosis 2009–2013, for all sarcomas
Federal State All sarcoma
Men Women
n Incidence (95%-CI)a n Incidence (95%-CI)a
Bayern 2929 7.5 (7.3–7.8) 3253 7.3 (7.0–7.6)
Berlin 586 5.9 (5.4–6.4) 617 5.4 (5.0–5.9)
Brandenburg 545 6.6 (6.0–7.2) 643 6.7 (6.1–7.2)
Bremen 154 7.3 (6.1–8.5) 169 6.2 (5.1–7.2)
Hamburg 413 7.8 (7.0–8.6) 506 8.7 (7.9–9.5)
Hessen 1222 5.9 (5.6–6.3) 1276 5.5 (5.2–5.9)
Mecklenburg-Vorpommern 349 6.2 (5.5–6.9) 422 6.6 (5.9–7.3)
Niedersachsen 1943 7.6 (7.3–8.0) 1903 6.5 (6.2–6.8)
Nordrhein-Westfalen 4238 7.8 (7.5–8.0) 4467 7.2 (7.0–7.4)
Rheinland-Pfalz 916 6.9 (6.4–7.3) 926 6.2 (5.8–6.7)
Saarland 253 7.4 (6.4–8.3) 272 6.6 (5.7–7.5)
Sachsen 1080 7.6 (7.1–8.0) 1162 6.9 (6.4–7.3)
Sachsen-Anhalt 451 5.5 (5.0–6.1) 491 5.2 (4.7–5.8)
Schleswig-Holstein 612 6.6 (6.0–7.1) 725 7.0 (6.5–7.6)
Thueringen 474 6.3 (5.7–6.9) 544 6.2 (5.6–6.8)
CI Confidence interval
aage-standardized incidence rates per 100,000 (European standard 1976)
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elderly people. Therefore, these cases are neither reported
to population-based cancer registries nor included in
hospital-based studies. In accordance with the literature
[8, 9], the age distribution for bone sarcomas in the study
presented here revealed a second peak at ages 10 to 19.
Hence, the median age at diagnosis of bone sarcomas was
much lower than that of other sarcomas.
GIST, liposarcomas, leiomyosarcomas, and fibrosarco-
mas were the most important histological groups in the
literature as well [5, 7, 8], although the respective
proportions differed considerably between studies. In the
literature, the complex neoplasia group was not catego-
rized as an individual entity.
The median age at diagnosis and the sex ratio differed
considerably between the histological groups. This is in
accordance with histological and molecular genetic find-
ings which show prominent differences between histolo-
gies [1, 3] and with other studies [5, 8].
The sarcoma incidence differed significantly between
federal states in Germany. In cancer registration, it is hard
to distinguish true differences in incidence rates from dis-
crepancies due to differences in completeness or coding
habits. As sarcoma is a rare cancer entity, numbers of
cases were low for federal states with fewer inhabitants.
Although incidence rates were calculated for a five-year
period, the validity of these results is therefore restricted.
Strengths and limitations
To our knowledge, this is the first study on sarcoma inci-
dence in Germany based on high-quality data from
population-based cancer registries. Analyses were based
on the latest data available at present. The study has high
external validity as it covered 87% of the German popula-
tion. In addition, the high number of cases allowed for de-
tailed stratified analyses, e.g. by individual histologies.
Finally, the study included all sarcomas based on histology
and not only sarcomas emerging from soft tissue.
A lack of completeness cannot be ruled out. However,
there are only estimates for ICD-10 C41- to C49. As well,
different coding habits between federal states may exist.
Moreover, there is a high proportion of sarcomas not other-
wise specified, which limits the analysis of histological sub-
groups. Finally, cases with unknown histologies were
excluded. Thus, some sarcomas may have been missed. It
has to be mentioned that all cases had been coded accord-
ing to the WHO classification of 2002 but in 2013 a novel
classification has been published. Furthermore, only local
pathology reports were available and to date it is unclear if
and in which cases reference pathology was performed
which would increase the reliability of subtyping sarcomas.
Conclusion
In summary, sarcoma incidence in Germany was exam-
ined based on data from population-based cancer
registries for the first time. Detailed sub-analyses strati-
fied by age, sex, and histology were performed. This
study confirms the significant increase in incidence of
GIST at the beginning of this century, which has also
been found in literature. It can partly be explained by
the increasing reliability of diagnosis due to the routine
use of markers like CD 117 and DOG1 as well as by the
increasing awareness of the diagnosis by physicians. The
incidence of soft tissue sarcomas (only men) as well as
of bone sarcoma stayed constant over time. In women,
the incidence of soft tissue sarcomas significantly de-
creased after the year 2009.
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